• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 2, Issue 2
  3. Author

Online ISSN: 2515-8260

Volume2, Issue2

EU early access - regulatory framework & practical considerations

    Debra Ainge

European Journal of Molecular & Clinical Medicine, 2015, Volume 2, Issue 2, Pages -

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

European Regulation 726/2004/EC (Article 83) and Directive 2001/83 (Article 5), provide a regulatory framework for access to investigational medicines outside the context of the clinical trial, allowing physicians to access potentially life-saving medicines that would otherwise be unavailable for their patients. Treatment with an investigational product represents an important option for patients suffering from serious or life threatening conditions where licensed alternatives are either unavailable or unsuitable for the patient. They can often be the only treatment option for disease areas of high unmet need such as rare diseases and orphan indications. Whilst the pharmaceutical industry has continued to focus on accelerating access to innovative new treatments by shortening the development timelines; increased regulatory challenges and delays due to pricing & reimbursement negotiations can result in delays of many years between positive phase III trials and commercial availability. Access Programs hence provide an important mechanism to bridge the time between clinical development, marketing authorisation and product launch. Although this EU framework exists, each member state has decided independently how and when to allow such access, and developed national rules and legislation to reflect this.
Keywords:
    As a result there is no single centralized European procedure for either single patient or cohort approaches indeed there are often more differences between the member states than similarities. Generally access is initiated by the physician
  • PDF (52 K)
  • XML
(2015). EU early access - regulatory framework & practical considerations. European Journal of Molecular & Clinical Medicine, 2(2), -.
Debra Ainge. "EU early access - regulatory framework & practical considerations". European Journal of Molecular & Clinical Medicine, 2, 2, 2015, -.
(2015). 'EU early access - regulatory framework & practical considerations', European Journal of Molecular & Clinical Medicine, 2(2), pp. -.
EU early access - regulatory framework & practical considerations. European Journal of Molecular & Clinical Medicine, 2015; 2(2): -.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 126
  • PDF Download: 150
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus